Staphylococcus aureus lipoteichoic acid inhibits platelet activation and thrombus formation via the Paf receptor by Waller, Amie K. et al.
Staphylococcus aureus lipoteichoic acid 
inhibits platelet activation and thrombus 
formation via the Paf receptor 
Article 
Published Version 
Creative Commons: Attribution 3.0 (CC­BY) 
Waller, A. K., Sage, T., Kumar, C., Carr, T., Gibbins, J. M. and 
Clarke, S. R. (2013) Staphylococcus aureus lipoteichoic acid 
inhibits platelet activation and thrombus formation via the Paf 
receptor. Journal of Infectious Diseases, 208 (12). pp. 2046­
2057. ISSN 1537­6613 doi: https://doi.org/10.1093/infdis/jit398 
Available at http://centaur.reading.ac.uk/33466/ 
It is advisable to refer to the publisher’s version if you intend to cite from the 
work. 
To link to this article DOI: http://dx.doi.org/10.1093/infdis/jit398 
Publisher: Oxford University Press 
All outputs in CentAUR are protected by Intellectual Property Rights law, 
including copyright law. Copyright and IPR is retained by the creators or other 
copyright holders. Terms and conditions for use of this material are defined in 
the End User Agreement . 
www.reading.ac.uk/centaur 
CentAUR 
Central Archive at the University of Reading 
Reading’s research outputs online
M A J O R A R T I C L E
Staphylococcus aureus Lipoteichoic Acid Inhibits
Platelet Activation and Thrombus Formation via
the Paf Receptor
Amie K. Waller,1,2 Tanya Sage,1,2 Christopher Kumar,1 Thomas Carr,1 Jonathan M. Gibbins,1,2 and Simon R. Clarke1,2
1School of Biological Sciences, and 2Institute for Cardiovascular and Metabolic Research, University of Reading, Whiteknights, United Kingdom
Impaired healing is common in wounds infected with the major human pathogen Staphylococcus aureus,
although the underlying mechanisms are poorly understood. Here, we show that S. aureus lipoteichoic acid
(LTA) inhibits platelet aggregation caused by physiological agonists and S. aureus and reduced platelet throm-
bus formation in vitro. The presence of D-alanine on LTA is necessary for the full inhibitory effect. Inhibition
of aggregation was blocked using a monoclonal anti-platelet activating factor receptor (PafR) antibody and
Ginkgolide B, a well-deﬁned PafR antagonist, demonstrating that the LTA inhibitory signal occurs via PafR.
Using a cyclic AMP (cAMP) assay and a Western blot for phosphorylated VASP, we determined that cAMP
levels increase upon platelet incubation with LTA, an effect which inhibits platelet activation. This was blocked
when platelets were preincubated with Ginkgolide B. Furthermore, LTA reduced hemostasis in a mouse tail-
bleed assay.
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Staphylococcus aureus is an important opportunistic
human pathogen and the cause of a large burden of
morbidity and mortality. The ability of the pathogen to
bind to and activate platelets, small (2–4 µm), blood
cells responsible for maintaining normal hemostasis
leads to the formation of platelet-bacteria thrombi on
the surface of heart valves, which is required for the de-
velopment of endocarditis since platelets attached to
damaged valves serve as foci for attachment of bacteria
circulating in the blood [1]. Several studies have shown
that S. aureus binds platelets and induces their aggrega-
tion. The pathogen possesses a variety of surface pro-
teins known as microbial surface components reacting
with adhesive matrix molecules (MSCRAMMs), some
of which are virulence factors in models of S. aureus
endocarditis. MSCRAMMs attach the bacterium to
platelets, either indirectly, by binding to ﬁbrinogen, si-
multaneously bound to the platelet surface by integrin
αIIbβ3, or by binding directly to αIIbβ3, thus inducing
outside-in signaling and platelet activation [2, 3]. Such
observations rely on washed S. aureus cells and thus
ignore the contribution of bacterial molecules secreted
into the extracellular milieu.
Although induction of thrombus formation by
S. aureus has been characterized extensively, infection
of wounds by this pathogen frequently results in im-
paired healing, the mechanisms of which are not fully
understood [4]. S. aureus extracellular proteins Efb in-
hibits platelet aggregation by binding to ﬁbrinogen [5].
Inhibition of platelet activity by Efb or pharmacological
antagonists causes decreased killing of S. aureus in
whole blood and increases the lethality of S. aureus in-
fection in a mouse model [6].
S. aureus lipoteichoic acid (LTA) was previously
shown to inhibit activation of platelets, although a role
in hemostasis its relevance to the S. aureus-platelet in-
teraction and the mechanism(s) by which inhibition is
achieved are not understood [7]. In this study, LTA in-
hibited activation of human platelets by physiological
agonists and S. aureus. Furthermore, LTA inhibits
platelet function and thrombus formation in vivo by
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binding platelet activating factor receptor (PafR), a phospholip-
id receptor that binds LTA and is associated with an increased
platelet intracellular cyclic adenosine monophosphate (cAMP)
concentration.
METHODS
Reagents
Collagen was obtained from Nycomed, thrombin, Ginkoglide
B, Mouse immunoglobulin G (IgG) from Sigma, and cross-
linked collagen-related peptide (CRP-XL) from R. Farndale
(University of Cambridge, UK). Anti-LTA (pagibaximab) was
provided by Biosynexus Inc. Anti-TLR2 (T2.5) was purchased
from eBioscience, anti-CD14 (UCH-M1) from AbD serotec,
anti-PafR from Cayman Chemical, anti-PhosphoVASP from
Cell Signaling Technology.
Bacterial Strains Used
Wild-type S. aureus SA113 was used with S. aureus SA113
ΔdltABCD [8], S. aureus SA113 ΔtagO [9], and S. aureus SA113
Δlgt [10]. S. aureus SEJ1 and isogenic strains ΔgdpP,
ΔgdpPΔltaS, and pCN34-ltaS were used for mutant studies
[11]. Bacillus subtilis 128 and Streptococcus pneumoniae D34
were used.
LTA Extraction
S. aureus was grown in BHI 37°C and centrifuged at 20 463 g
for 15 minutes. The pellet was resuspended in 50% butanol/
water. LTA was resuspended in a 1 mM sodium acetate, 15%
1-propanol buffer followed by a 15%–60% 1-propanol elution
gradient, dialyzed against dH20, and the concentration deter-
mined by phosphate assay [12].
LTA From S. aureus Culture Supernatants
S. aureus cultures were centrifuged at c. 12 000 g for 10 minutes
to remove cells. In total, 2.3M (NH4)2SO4 was added to the
supernant overnight at 4°C. The supernatant was centrifuged at
20 000 g for 20 minutes at 4°C and the pellet resuspended in 2
mL of phosphate-buffered saline (PBS). To standardize super-
natant preparations, including those lacking LTA, proteins
carried over were quantiﬁed by Bradford assay. Where appro-
priate, LTA concentrations were determined as above.
Preparation of Human Platelets
Human blood was obtained from healthy volunteers who gave
informed consent. Ethical approval was obtained from the Uni-
versity of Reading Research Ethics Committee. Platelets were
prepared as described elsewhere [13]. In total, 4 × 108 platelets/
mL were incubated for 15 minutes with LTA and stimulated by
agonists. Aggregation was measured in an optical aggregometer
(Chronolog). Percentage inhibition of aggregation by LTA was
calculated by dividing maximal aggregation of LTA-treated
samples by the aggregation achieved by the given agonist alone.
Centrifuged S. aureus were washed 3 times in Tyrodes buffer
and adjusted for a ﬁnal experimental OD600 0.3. Aggregation
was measured up to 15 minutes.
Flow Cytometry
In total, 5 µL of platelet-rich plasma (PRP; 4 × 108 cells/mL)
was incubated with anti-PafR (50 µg/mL), IgG2a (50 µg/mL),
or Tyrode buffer for 30 minutes, then incubated with various
concentrations of FITC-LTA for 15 minutes. Fluorescence in-
tensity of the sample was measured using a BD Accuri C6 ﬂow
cytometry; 10 000 events per sample were measured.
Measurement of Intracellular [Ca2+]i
Platelets were preloaded with the ﬂuorescent dye Fluo-4NW as
described elsewhere [13]. PRP was preincubated with LTA for
15 minutes before being stimulated with CRP-XL, and calcium
release was measured using a Fluoroskan reader (Thermolab
Systems) at 485/530 nm.
In Vitro Thrombus Formation
Whole citrated blood was perfused through a Vena8Biochip
(Cellex, Dublin). Z-stack images were taken every 30 seconds
using a Nikon eclipse (TE2000-U) microscope; data were ana-
lyzed using Slidebook5 software (Intelligent Imaging Innova-
tions, Denver, USA)
Tail-bleeding Assay
Procedures were approved by the University of Reading Animal
Ethics Committee and the Home Ofﬁce. Sixteen age-matched
C57BL/6 mice were killed using ketamine (80 mg/kg) and xyla-
zine (5 mg/kg) administered intraperitoneally prior to a tail
biopsy. Time to cessation of bleeding was measured up to 20
minutes.
RESULTS
S. aureus LTA Inhibits Platelets Aggregation by Various Platelet
Agonists
LTA is found at high concentrations within S. aureus cells and
the extracellular milieu [14] and could thus interact with plate-
lets during infection. LTA present in the supernatant and
S. aureus cell envelope have the same structure [15]. In this
study we investigated LTA inhibition of platelet aggregation.
First, we conﬁrmed equal inhibitory activity for LTA puriﬁed
from the supernatant and cells (Supplementary Figure 1A). For
efﬁciency, remaining experiments used LTA extracted from the
cell envelope. To determine which signaling pathways LTA in-
hibits, aggregation assays were performed with well-character-
ized platelet agonists. Puriﬁed LTA from S. aureus SA113 was
preincubated with washed human platelets before activation
with CRP-XL, a collagen receptor Glycoprotein VI selective
agonist (Figure 1Ai and 1Aii), platelet activating factor (paf;
Figure 1Bi and 1Bii) or thrombin (Figure 1Ci and 1Cii). LTA
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inhibited aggregation in a dose-dependent manner with all ago-
nists. LTA was incubated for varying periods of time with
washed platelets to observe any time-dependent effects on ag-
gregation. Using 4 µg/mL LTA, inhibition of aggregation in-
creased in a time-dependent manner (Figure 1Di and 1Dii).
Platelet activation was inhibited over extended time periods
(Supplementary Figure 1B). The highest concentration of LTA
used with thrombin (3 µg/mL), CRP-XL (4 µg/mL), and paf
(16 µg/mL) as platelet agonists produced a 40%, 85%, and 50%
reduction in platelet aggregation respectively, thus showing
LTA to be a potent inhibitor of platelet aggregation.
Whole bacterial cells stimulate platelet activation via forma-
tion of ﬁbrinogen or ﬁbronectin bridges between integrin
αIIbβ3 and S. aureus MSCRAMMs [3, 16, 17]. Having demon-
strated LTA inhibition of platelet activation by physiological
agonists, we examined the ability of exogenous LTA to inhibit
Figure 1. LTA from Staphylococcus aureus inhibits platelet aggregation. Washed human platelets (4 × 108 cells/mL) or PRP were preincubated with LTA
or tyrodes buffer and stimulated with various platelet agonists. Aggregation was measured as change in light transmission. Ai–Di, Representative aggrega-
tion traces of platelets incubated with LTA and stimulated with various platelet agonists. All aggregation traces commence upon addition of agonist. Aii–
Dii, Data are plotted as percentage inhibition of aggregation or percentage aggregation (vehicle treated representing 100% aggregation) and represent
mean values ± SEM. A, Platelets were pre-incubated with LTA at a range of concentrations followed by stimulation with CRP-XL (0.5 µg/mL). Aggregation
was measured for 90 seconds. B, Platelets were preincubated with LTA at a range of concentrations followed by stimulation with Paf (37.5 µg/mL). Aggre-
gation was measured for 90 seconds. C, Platelets were pre-incubated with LTA at a range of concentrations followed by stimulation with thrombin (0.05
units/mL). Aggregation was measured for 90 seconds. D, Platelets were preincubated with LTA (4 µg/mL) for 8, 10, 12, 14, and 16 minutes followed by
stimulation with CRP-XL (0.5 µg/mL). Aggregation was measured for 90 seconds. E, PRP was pre-incubated with various concentrations of LTA for 15
minutes followed by stimulation with whole S. aureus SA113 cells (2 × 108 cells/mL). Aggregation was measured for up to 20 minutes. Data are plotted as
increase in lag time and represent mean values ± SEM. *P < .05 Abbreviations: CRP-XL, cross-linked collagen-related peptide; LTA, lipoteichoic acid; PRP,
platelet-rich plasma; SEM, standard error of the mean.
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S. aureus induced platelet aggregation in PRP (Figure 1E). In-
creasing LTA concentrations increased the lag time to platelet
aggregation.
To conﬁrm that the observed inhibition was due to LTA
rather than a copurifying contaminant, platelets were pretreat-
ed with monoclonal anti-LTA and LTA before stimulation with
CRP-XL. This blocked the LTA inhibitory effect (Figures 2Ai
and 2Aii). An isotype (IgG1) matched control had no effect
(results not shown). Lipoproteins that can copurify with LTA
are sometimes responsible for the immunological activities that
have been assigned to LTA [18]. S. aureus wall teichoic acid
(WTA) has a similar structure to LTA. LTA was extracted from
SA113 ΔtagO and SA113 Δlgt, which lack WTA and lipopro-
teins, respectively, and tested in the same manner. LTA extract-
ed from both of these strains inhibited platelets to the same
levels as LTA from SA113 (Supplementary Figure 2), conﬁrm-
ing LTA platelet inhibitory activity and excluding any effect
from lipoproteins or WTA.
To determine whether this inhibition was restricted to
S. aureus LTA, the molecule was extracted and puriﬁed from
2 other Gram-positive bacteria and tested for its ability to
inhibit platelet aggregation. Bacillus subtilis is a nonpathogenic
species that, like S. aureus, produces LTA with a 1,3-linked
polyglycerolphosphate chain tethered to the membrane by a di-
glucosyl-diacylglycerol glycolipid. Glycerolphosphate subunits
are esteriﬁed with D-alanine [19]. Streptococcus pneumoniae
LTA consists of a repeating ribitol-galactose backbone with
phosphocholine and D-alanine residues attached [20]. S. pneu-
moniae LTA showed no inhibition, whereas B. subtilis LTA
caused a dose-dependent inhibition up to a maximum of 20%
(Figure 2Bi, 2Bii, and 2C); we were unable to solubilize high
enough concentrations of B. subtilis LTA to achieve saturation.
The Supernatant of an S. aureus Mutant Which Lacks LTA Is
Unable to Inhibit Platelet Activation
S. aureus mutant strains lacking LTA only grow under osmoti-
cally stabilizing conditions or by acquiring compensatory mu-
tations [11]. S. aureus SEJ1 (RN4220 spa) was used to construct
an LTA-deﬁcient (ΔltaS) strain, but in order for the ΔltaS to be
viable, gdpP must also be mutated [11]. Cells of the parental
SEJ1 and isogenic strains ΔgdpP, ΔgdpPΔltaS, and ΔgdpPΔltaS
containing pCN34-ltaS, a complementation plasmid expressing
ltaS from its native promoter, were grown and OD600 of c. 0.5
and LTA in the supernatant was precipitated using (NH4)2SO4.
To ensure that consistent amounts of material were used, the
amount of protein precipitated along with the LTA was deter-
mined by Bradford assay to standardize the preparations. As
expected, only supernatant from the ΔgdpPΔltaS lacked LTA
upon Western blotting (results not shown). In each experiment,
precipitate was used to a ﬁnal concentration of 10 μg/mL of
exoprotein. Supernatant from all strains, except ΔgdpPΔltaS,
inhibited platelet activation (Figure 2Di and 2Dii).
We were unable to assess the ability of these stains to induce
platelet aggregation, as S. aureus RN4220 proved unable to
induce aggregation despite incubations of up to 1 hour (results
not shown).
LTA Produced From S. aureus ΔdltABCD Has a Reduced Ability
to Inhibit Platelet Aggregation
D-alanine residues are important for various functions of LTA
in different biological systems. In S. aureus the addition of D-
alanine to the LTA chain is encoded by the dlt operon [8]. LTA
was extracted and puriﬁed from S. aureus SA113 ΔdltABCD
and preincubated with washed human platelets. LTA puriﬁed
from S. aureus SA113 ΔdltABCD showed a signiﬁcant reduc-
tion (c. 60%) in its ability to inhibit the platelet aggregation
(Figure 3Ai), compared to LTA from the parental wild-type
strain (Figure 3Aii). Activation of platelets by whole S. aureus
ΔdltABCD was indistinguishable from the parent (results not
shown); thus it appears that LTA needs to be released from S.
aureus to exert its inhibitory effect.
LTA Inhibits [Ca2+] Mobilization
During the initial stages of platelet activation, intracellular
calcium stores are mobilized to modulate downstream sig-
naling. In order to further characterize the effect of LTA on
platelets during the early stages of aggregation, an assay to de-
termine intracellular calcium mobilization and inﬂux was per-
formed. Platelets preincubated with LTA showed a signiﬁcantly
reduced ability to mobilize calcium when challenged with CRP-
XL compared to a vehicle treated control (P < .001; Figure 3Bi).
Over the course of the assay this equated to a 70% reduction in
intracellular calcium levels (Figure 3Bii). Because of its reduced
inhibitory potency, calcium release stimulated by LTA from
SA113 ΔdltABCD was assayed. From the mean trace of ﬂuores-
cence over the course of the experiment a repeatable difference
was observed (Figure 3Bi). The peak end point ﬂuorescence
caused by LTA derived from wild-type and ΔdltABCD strains
were signiﬁcantly different (Figure 3Bii).
LTA Inhibition of Platelet Activation Can Be Blocked Using
Anti-Paf Receptor Antibodies and Ginkgolide B
In different cell types, LTA has previously been reported to
bind 4 receptors CD14 [21], CD36 [22], TLR2 [23], and platelet
activating factor receptor (PafR) [24]. Monoclonal antibodies
with blocking activity for TLR2 and CD14, along with anti-
PafR and –CD36 monoclonal antibodies were each tested for
their ability to block LTA inhibition (Figure 4Ai). The anti-
CD14 and –PafR antibodies were isotype matched. No signiﬁ-
cant blocking of LTA inhibition occurred with the anti-CD14,
-CD36, -TLR2, or mouse IgG (negative control). However
anti-PafR abolished LTA-mediated inhibition (Figure 4Ai and
4Aii). Furthermore, ginkgolide B, a speciﬁc PafR antagonist
[25] blocked LTA-mediated platelet inhibition (Figure 4Bi),
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Figure 2. The inhibition is due to the presence of Staphylococcus aureus LTA. A, Washed human platelets (4 × 108 cells/mL) were preincubated with
anti-LTA antibody (1 µg/mL) before incubation for 15 minutes with LTA (2 µg/mL) followed by stimulation with CRP-XL (0.5 µg/mL). Aggregation was mea-
sured as change in light transmission for 90 seconds. NB: In Ai, lines representing platelets treated with 2 µg/mL + anti-LTA antibodies and untreated
platelets, overlap extensively. B, Washed platelets were incubated for 15 minutes with LTA extracted from S. aureus SA113 (4 µg/mL), Bacillus subtilis, or
Streptococcus pnuemoniae D34 (12.5 µg/mL) followed by stimulation with CRP-XL (0.5 µg/mL). C, Washed platelets were incubated for 15 minutes with
LTA extracted from B. subtilis at a range of concentrations followed by stimulation with CRP-XL (0.5 µg/mL). D, Washed platelets were incubated for 15
minutes with supernatant from S. aureus SEJ1, SEJ1 ΔgdpP, SEJ1 ΔltaS ΔgdpP or SEJ1 ΔltaS ΔgdpP pCN34-ltaS (10 µg/mL), followed by stimulation
with CRP-XL (0.5 µg/mL). (Ai, Bi, Di) Representative aggregation traces of washed platelets. Aggregation was measured for 90 seconds. (Aii, Bii, C, Dii)
Data are plotted as percentage inhibition of aggregation represent mean values ± SEM. *P < .05, **P < .001. Abbreviations: CRP-XL, cross-linked collagen-
related peptide; LTA, lipoteichoic acid; SEM, standard error of the mean.
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reducing it to 0% inhibition (Figure 4Bii). These data demon-
strate a role for PafR on platelets as an LTA receptor.
Using ﬂow cytometry, anti-PafR antibody abolished binding
of FITC labelled LTA to platelets, demonstrating that PafR is
the only receptor for the molecule (Figure 4C).
We tested whether anti-PafR antibody blocking was due to a
nonspeciﬁc interaction with LTA, rather than blocking of PafR.
We were unable to deplete samples of their inhibitory effect
using anti-PafR antibodies, linked to protein A coated magnetic
beads (results not shown). The blocking effect of anti-PafR was
not due to cross-reactivity with LTA.
LTA Causes Raised cAMP Levels to Cause Inhibition of Platelet
Activation
Our ﬁnding that LTA inhibited Ca2+ ﬂux in platelets led us to
hypothesize that an increase of cAMP would occur in platelets
upon incubation with LTA, which could be blocked with gink-
golide B. Increased cAMP concentrations attenuate Ca2+ mobi-
lization, which is necessary for platelet activation. In platelets,
raised levels of cAMP result in increased levels of phosphorylat-
ed vasodilator-stimulated phosphoprotein (VASP) [26]. Quali-
tative assessment of VASP phosphorylation was carried out by
Western blot. Samples were prepared that had been pretreated
with ginkgolide B, incubated with LTA, and were compared
with control samples (Figure 5A). Levels of phosphorylated
VASP, shown by the upper band which represents phosphory-
lation at residue Ser 157 [26], were increased in both the posi-
tive control (prostacyclin treated) and LTA-treated samples
indicating a possible role for increased platelet cAMP concen-
trations in LTA-mediated inhibition. To conﬁrm that this
inhibition occurred via PafR, 2 samples were treated with gink-
golide B and one of these with LTA also. In both samples no
Figure 3. LTA from Staphylococcus aureus ΔdltABCD has a reduced ability to inhibit platelet aggregation. A, Washed human platelets (4 × 108 cells/mL)
were incubated for 15 minutes with LTA extracted from S. aureus strains SA113 or SA113 ΔdltABCD (4 µg/mL) followed by stimulation with CRP-XL (0.5
µg/mL). B, Platelets in PRP were preloaded with Fluo-4NW dye. Platelets were then pre-incubated with LTA extracted from S. aureus strains SA113 or
SA113 ΔdltABCD (4 µg/mL) or Tyrodes buffer for 15 minutes followed by stimulation by CRP-XL (0.5 µg/mL). Intracellular mobilization of calcium was mea-
sured by spectroﬂuorimetry for 120 seconds. Ai, Representative aggregation traces of washed platelets. Aggregation was measured for 90 seconds. Ai,
Representative aggregation trace. Aii, Data are plotted as percentage maximum ﬂuorescence (vehicle treated representing 100% aggregation) and repre-
sent mean values ± SEM. Bi, Representative calcium ﬂux trace. Bii, Data are plotted as percentage endpoint ﬂuorescence (vehicle treated representing
100% aggregation) and represent mean values ± SEM. *<.01, **P < .005. Abbreviations: CRP-XL, cross-linked collagen-related peptide; LTA, lipoteichoic
acid; SEM, standard error of the mean.
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increase in VASP phosphorylation was observed, demon-
strating that VASP phosphorylation resulting from LTA treat-
ment can be blocked by the PafR antagonist. Furthermore,
supernatant from S. aureus SEJ1 and SEJ1 ΔgdpP were able to
cause VASP phosphorylation. Supernatant from S. aureus SEJ1
ΔgdpP ΔltaS was not able to induce phosphorylation, but the
Figure 4. LTA acts through PafR to inhibit platelets. A, Washed platelets were incubated with anti-PafR (4 µg/mL), anti-TLR2 (4 µg/mL), anti-CD14 (4 µg/
mL), Mouse IgG (4 µg/mL) or Tyrodes buffer for 30 minutes before addition of LTA (4 µg/mL) for 15 minutes. B, Washed platelets were incubated with Gink-
golide B (2 mM) or Tyrodes buffer for 30 minutes before the addition of LTA (4 µg/mL) for 15 minutes. Platelets were then stimulated with CRP-XL (0.5 µg/
mL). NB: In Bi, lines representing platelets treated with 4 µg/mL LTA + 2 µM Ginkgolide B and 0 µg mL−1 LTA + 2 µM Ginkgolide B, overlap extensively. A
and B, Platelet aggregation was measured as change in light transmission and recorded for 90 seconds. Data are plotted as percentage inhibition of aggre-
gation (normalized so that LTA treatment represents 100% inhibition) and represent mean values ± SEM. *P < .0001, **P < .01. C, PRP (4 × 108 cells/mL)
was incubated for 30 minutes with anti-PafR (50 µg/mL), IgG2a (50 µg/mL) or Tyrode buffer before the addition of FITC-LTA at several concentrations for 15
minutes. Samples were run through a BD Accuri C6 ﬂow cytometer and median ﬂuorescence was recorded. Data are plotted as percentage median in-
crease in ﬂuorescence when compared to a Tyrode buffer only control and represent mean values ± SEM. Abbreviations: CRP-XL, cross-linked collagen-
related peptide; IgG, immunoglobulin G; LTA, lipoteichoic acid; PafR, platelet activating factor receptor; SEM, standard error of the mean.
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effect was restored in supernatant of the complemented strain
(Figure 5A). These data provide genetic proof of the role of
LTA in VASP phosphorylation.
The cAMP concentration in platelet lysates was assayed
(Figure 5B). A mean c. 350% increase of cAMP concentration
occurred in platelets incubated with LTA. In platelets pretreated
with ginkgolide B, no increase was observed, correlating with
the results from the Western blot for VASP phosphorylation.
No increase in VASP phosphorylation or cAMP levels was ob-
served in samples treated solely with ginkgolide B.
LTA Reduces Platelet Thrombus Formation In Vitro and Causes
Extended Bleeding Time In Vivo
In order to investigate whether LTA could inhibit thrombus
formation in whole blood and under arterial ﬂow conditions,
whole human blood was perfused through collagen coated bio-
chips in the presence of tyrodes buffer and LTA from wild-type
S. aureus or from S. aureus SA113 ΔdltABCD (Figure 6A). In
blood pretreated with LTA, a signiﬁcantly reduced thrombus
size, compared to the vehicle treated control, was observed
(P < .001; Figure 6A and 6B). Additionally peak ﬂuorescence
was reduced by approximately 85% (Figure 6C). Blood treated
with LTA extracted from SA113 ΔdltABCD showed a slower
rate of thrombus formation however at the end of the 10
minutes the thrombi present were no different in size than
vehicle treated (P > .05; Figure 6B). The mean peak ﬂuorescence
of thrombi formed in the presence of LTA from S. aureus
ΔdltABCD showed no difference to that of the control but was
signiﬁcantly different than wild-type LTA treated (P < .05;
Figure 6C). Inhibition of thrombus formation in blood was
Figure 5. Incubation of platelets with LTA increases cAMP concentrations. A, Platelets (8 × 108 cells/mL) were pretreated with either Ginkgolide B (2
mM) or tyrodes buffer for 30 minutes. Platelets were then treated with LTA from Staphylococcus aureus SA113 (4 µg/mL), PGI2 (0.25 µg/mL), supernatant
from S. aureus SEJ1, SEJ1 ΔgdpP, SEJ1 ΔltaS ΔgdpP or SEJ1 ΔltaS ΔgdpP pCN34-ltaS (10 µg/mL), or Tyrodes buffer. Lysates were immunoblotted with
an anti-VASP antibody. B, Platelets (8 × 108 cells/mL) were pretreated with either Ginkgolide B (2 mM) or tyrodes buffer for 30 minutes. Platelets were
then treated with LTA (4 µg/mL), PGI2 (0.25 µg/mL), or tyrodes buffer. Samples were then assayed for cAMP concentration determined by ELISA. Data rep-
resent mean values ± SEM. *P < .05. Abbreviations: cAMP, cyclic adenosine monophosphate; ELISA, enzyme-linked immunosorbent assay; LTA, lipoteichoic
acid; SEM, standard error of the mean; VASP, vasodilator-stimulated phosphoprotein.
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consistent with the reduced platelet function observed in
washed platelets (Figure 1Ai–Eii).
To substantiate these ﬁndings, an in vivo mouse model of
bleeding was used. Previous reports have proposed that mouse
platelets may lack PafR [27]; however, by Western blotting, we
identiﬁed a c. 48 kDa band in mouse platelets that comigrates
with PafR on human platelets (Supplementary Figure 3A). Sim-
ilarly, Paf was a weak agonist, compared to collagen, for mouse
and human platelet activation (Supplementary Figure 3B) and
LTA inhibited platelet activation by collagen in mouse platelets
(Supplementary Figure 3C). The effect of LTA on maintenance
of hemostasis was measured by a tail bleed assay. Infusion of S.
aureus LTA into rodents does not induce shock or affect blood
pressure [28]. The mean bleeding time of vehicle-treated (PBS)
mice was 340 seconds following tail biopsy (Figure 7). In LTA-
treated mice mean time to cessation of bleeding increased sig-
niﬁcantly (P < .01), more than doubling to 690 seconds.
LTA has multiple roles on many different host cell types, and
we cannot rule out an additional role for the endothelium in
the tail bleeding experiments. But by measuring thrombus for-
mation in the absence of endothelial cells, we have conﬁrmed a
role for LTA alteration of platelet function in thrombus forma-
tion. Taken together, these data demonstrate that LTA has a role
in the inhibition of thrombosis and hemostasis.
DISCUSSION
The interplay between S. aureus and its human host is complex.
Numerous host and pathogen factors are involved in the inter-
action, and many have multiple activities. S. aureus LTA is a
polymeric glycerol-phosphate molecule that can be ﬁxed to the
cell membrane by a lipid anchor and has a well-established role
in several host-pathogen interactions. Although attached to the
cell envelope, LTA is also released into the S. aureus superna-
tant, a process accelerated by some antibiotics [29]. In vivo
during S. aureus infections, LTA has been detected, albeit by a
different method to ours, at up to 10 µg/mL [30]. S. aureus
modiﬁes LTAwith D-alanine, which confers multiple effects on
its function. Interestingly, the presence of D-alanine on S.
aureus teichoic acids confers resistance to platelet microbicidal
protein, a product of activated platelets [31]. We have shown
that D-alanylation increases the platelet-inhibitory potency of
Figure 6. LTA inhibits thrombus formation in vitro. A, Platelets within whole human blood were labelled with a lipophilic dye DIOC6. Whole blood was
then treated with (Ai) tyrodes buffer, (Aii) LTA extracted from Staphylococcus aureus strains SA113 (10 µg/mL) or (Aiii) LTA extracted from S. aureus strain
SA113 ΔdltABCD (10 µg/mL) for 15 minutes. Whole blood was then perfused through collagen coated (400 µg/mL) Vena8Biochip at a ﬂow rate of
20 dynes cm−2. Formation of thrombi was recorded using a Z stack capture every 30 seconds for 10 minutes using a Nikon eclipse (TE2000-U) microscope.
Thrombus ﬂuorescence intensity was calculated using Slidebook 5 software. B, Data represents mean of thrombi volume over the experiment duration. C,
Data represent mean ± SEM of peak ﬂuorescence intensity. *P < .05. **P < .01. Abbreviations: LTA, lipoteichoic acid; SEM, standard error of the mean.
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LTA. Thus the dltABCD operon plays a dual role in protecting
S. aureus against the bactericidal effects of platelet activation.
Interestingly, LTA from wild-type S. aureus was more inhibi-
tory than that from the isogenic dltABCD mutant. However,
there was no difference in the ability of S. aureus cells to induce
platelet activation in the absence of exogenous LTA. Both D-
alanine residues and lipid anchor have been reported to be re-
quired for stimulation of cytokine production in human whole
blood and mouse monocytes [32]. This may explain our obser-
vation, as the lipid, which is usually embedded within the bac-
terial membrane, would only be exposed to host cell receptors
upon release of LTA. Alternatively, measurements of the S.
aureus cell wall show it to be sufﬁciently thick that the com-
monly depicted schematic, in which LTA chains extend
through the cell wall and are exposed on the surface, may be in-
correct [33].
Many of the ascribed functions of LTA have been determined
using commercial preparations [24, 34], which were subsequently
shown to contain contaminants responsible for the activity [10,
18, 35]. Thus results obtained using such preparations may
remain open to question. We conﬁrmed that properly puriﬁed
LTA does inhibit platelet activation. Moreover, LTA inhibits acti-
vation of platelets by multiple physiological agonists and whole
S. aureus cells, each of which trigger activation in different ways,
suggesting that LTA blocks a common downstream effect. Ca2+
mobilization, a critical stage in platelet activation, was inhibited
and is accompanied by increased cellular cAMP concentrations.
LTA interacts with PafR, a cell surface receptor that couples to
different G proteins to activate cellular responses that differ
between cell types [36–40]. In platelets, the G-proteins that
interact with PafR remain to be determined. However, PafR does
not signal through the pertussis toxin-sensitive Gi and Go pro-
teins in platelets [41]. It is well documented that platelet GPCRs
can inﬂuence cellular cAMP concentrations, thereby inhibiting
Ca2+ ﬂux [42]. In other cells, PafR interacts with multiple G pro-
teins, resulting in activation of distinct signaling pathways.
Indeed, differential PafR signaling in response to agonists and
inverse agonists has been reported [43]. Leukocyte responses to
Paf utilize pertussis toxin-insensitive and -sensitive G protein(s)
[44, 45]. In CHO cells, Paf activation of p38 MAPK occurs
through Gq protein, but Paf activation of extracellular signal-
regulated kinases 1 and 2 occurs via signaling through Go
protein [46]. PafR signaling in HUVECs, including cAMP pro-
duction by stimulation of adenylate cyclase, occurs via the Gq
protein [47]. The exact nature of the signaling events that lead to
the increased platelet cAMP levels will be the topic of future
pharmacological studies.
The ability of S. aureus to induce platelet activation is well
documented [3] and is presumed to be important in the devel-
opment of bacterial endocarditis. S. aureus therefore possesses
the ability both to positively and to negatively inﬂuence throm-
bus formation. It seems questionable that platelet activation is
advantageous for any bacteria. In doing so, a pathogen
becomes enmeshed in a thrombus that can lead to the death of
the host, leaving the bacterium unable to continue the infec-
tious cycle. Indeed, the ability to inhibit platelet activation pre-
sumably confers an advantage to pathogens during infection.
Because they are rich sources of bioactive molecules, some of
which are bactericidal, platelets have roles in modulating other
cellular functions, including those of the innate and acquired
immune systems [48] and as such serve to alert the host to
the presence of an infection. Activated platelets can engulf
S. aureus, although whether this occurs in vivo or has any role
in infection remains to be determined [49]. Furthermore, direct
interaction with activated platelets induces hyperactivation
of neutrophils, enhancing their already potent antibacterial
activity [50].
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